Summary
Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
Market Segment as follows:
By Type
Creams
Tablets
Patches
Rings
By Application
Topical Estrogen
Systemic Estrogen
Non-hormonal Therapy
By Company
Allergan
Pfizer
Shionogi
Novo Nordisk
Teva Pharmaceutical
Bayer.
The main contents of the report including:
Section 1:
Product definition, type and application, global and China market overview;
Section 2:
Global and China Market competition by company;
Section 3:
Global and China sales revenue, volume and price by type;
Section 4:
Global and China sales revenue, volume and price by application;
Section 5:
China export and import;
Section 6:
Company information, business overview, sales data and product specifications;
Section 7:
Industry chain and raw materials;
Section 8:
SWOT and Porter's Five Forces;
Section 9:
Conclusion.
Summary:
Get latest Market Research Reports on Postmenopausal Vaginal Atrophy Treatment . Industry analysis & Market Report on Postmenopausal Vaginal Atrophy Treatment is a syndicated market report, published as Global and China Postmenopausal Vaginal Atrophy Treatment Market Research by Company, Type & Application 2013-2025. It is complete Research Study and Industry Analysis of Postmenopausal Vaginal Atrophy Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.